AQEMIA, a pioneering MedTech company that teaches atomic-scale physics to a generative AI to invent innovative medicines, is expanding to the UK.
The Parisian firm鈥檚 funding has topped $100 million with a new $38m round, led by new investor Cathay Innovation, less than a year after the previous one.
It is now scheduled to open a London office in the King鈥檚 Cross area in January 2025.
AQEMIA says this follows the successful validation of its drug discovery platform in internal preclinical programs and pharmaceutical partnerships, particularly in oncology. It also has a $140m collaboration with Sanofi, announced in December 2023.
The funding will support AQEMIA鈥檚 development goals, including preparations for clinical trials and expansion worldwide.
Former Babylon UK chief appointed CEO at Doctor Care Anywhere
鈥淭his is a transformative moment for AQEMIA,鈥� said Maximilien Levesque, CEO and co-founder.聽
鈥淟ess than a year after our last round, this successful fundraising and the opening of our new London office mark significant strides toward our ambition to accelerate the discovery of new medicines on a global scale.聽
鈥淧artnering with Cathay Innovation brings international expertise, particularly in the US and Asia, reinforcing our vision and mission. With this momentum, we are poised to advance to clinical trials, bringing us closer to delivering life-changing treatments to patients in need.鈥�
Historical investors Wendel, Bpifrance Large Venture, Eurazeo and Elaia followed on in the round.
鈥淲e have long been committed to supporting visionary entrepreneurs who harness the transformative potential of AI to reshape the healthcare industry,鈥� said Jacky Abitbol, partner at Cathay Innovation.聽
鈥淎QEMIA embodies the future of drug discovery, combining the power of AI with quantum mechanics鈥� it aims to profoundly transform the molecule research and pharmaceutical industry as a whole.聽
鈥淥ur partnership goes beyond capital support; we are putting to good use our experience in scaling AI-driven companies all over the world, particularly across US and Asia, as AQEMIA accelerates its path to the clinic and expands its global impact.鈥�
Ulster University spinout targeting obesity & diabetes wins funding